Cantor Fitzgerald LP’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge.

Howard Lutnick, chairman and CEO of investment firms Cantor Fitzgerald and BGC Group, told the U.S. Senate Committee on Commerce, Science and Transportation that he would divest “all of my interests, my business interests, all of my assets, everything.”

Mr Lutnick has taken aim at Ireland's trade surplus, arguing it has come at the expense of the US. Meanwhile, his firm, Cantor Fitzgerald has a significant presence in Ireland, with offices in Cork, D

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $160.00 price objective on the stock. The consensus estimate for DoorDash’s current full-year earnings is $0.27 per share. Get ...

Howard Lutnick, the wealthy Wall Street executive whom President Trump has tapped to lead the Department of Commerce, detailed a complex network of financial holdings on Friday as he prepared to face scrutiny from lawmakers during a confirmation hearing next week.

Cantor Fitzgerald raised the firm’s price target on Tesla (TSLA) to $425 from $365 and keeps a Neutral rating on the shares. Tesla’s adjusted

Cantor Fitzgerald has a “Overweight” rating and a $67.00 price objective on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Get ...

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish China stance.

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of January 29,

Cantor Fitzgerald currently has a “Overweight” rating and a $9.00 target price on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share ...